[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100496640":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":85,"collaborators":87,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":95,"sex":101,"minAge":102,"maxAge":7,"enrollmentInfo":103,"targetDuration":7,"studyType":106,"phases":7,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":115,"whyStopped":7,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"no intervention (observational study)","No intervention (observational study)",[13],{"name":14,"affiliation":15,"role":16},"Stefan Hohaus, MD","Fondazione Policlinico Universitario A. Gemelli","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","06-30154180","stefan.hohaus@unicatt.it",[23,48,69],{"facility":24,"status":7,"city":25,"state":7,"zip":7,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Istituto Nazionale Tumori Fondazione \"G. Pascale\" IRCCS","Naples","Italy","IT",{"type":29,"coordinates":30},"Point",[31,32],14.26811,40.85216,{"lat":32,"lon":31},[35,38,41,44,46],{"name":36,"role":19,"phone":7,"phoneExt":7,"email":37},"Antonello Pinto, MD","a.pinto@istitutotumori.na.it",{"name":39,"role":19,"phone":7,"phoneExt":7,"email":40},"Mariangela Saggese","m.saggese@istitutotumori.na.it",{"name":42,"role":43,"phone":7,"phoneExt":7,"email":7},"Rosaria De Filippi, MD","SUB_INVESTIGATOR",{"name":45,"role":43,"phone":7,"phoneExt":7,"email":7},"Umberto Falcone, MD",{"name":47,"role":43,"phone":7,"phoneExt":7,"email":7},"Francesco Volzone, MD",{"facility":49,"status":7,"city":50,"state":7,"zip":7,"country":26,"countryCode":27,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Fonadazione Policlinico Universitario A. Gemelli","Roma",{"type":29,"coordinates":52},[53,54],11.10642,44.99364,{"lat":54,"lon":53},[57,58,61,63,65,67],{"name":14,"role":19,"phone":7,"phoneExt":7,"email":21},{"name":59,"role":19,"phone":7,"phoneExt":7,"email":60},"Arianna Errico","errico.arianna@gmail.com",{"name":62,"role":43,"phone":7,"phoneExt":7,"email":7},"Silvia Bellesi, MD",{"name":64,"role":43,"phone":7,"phoneExt":7,"email":7},"Elena Maiolo, MD",{"name":66,"role":43,"phone":7,"phoneExt":7,"email":7},"Flaminia Bellisario, MD",{"name":68,"role":43,"phone":7,"phoneExt":7,"email":7},"Francesco D'Alò, MD",{"facility":70,"status":7,"city":50,"state":7,"zip":7,"country":26,"countryCode":27,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"Istituti Fisioterapici Ospitalieri -Istituto Regina Elena",{"type":29,"coordinates":72},[53,54],{"lat":54,"lon":53},[75,78,81,83],{"name":76,"role":19,"phone":7,"phoneExt":7,"email":77},"Maria Rizzo, MD","maria.rizzo@ifo.it",{"name":79,"role":19,"phone":7,"phoneExt":7,"email":80},"Elena Papa","ematologia@ifo.it",{"name":82,"role":43,"phone":7,"phoneExt":7,"email":7},"Francesco Marchesi, MD",{"name":84,"role":43,"phone":7,"phoneExt":7,"email":7},"Giulia Regazzi, PhD",{"type":86,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[88,90],{"name":89,"class":6},"Istituti Fisioterapici Ospitalieri",{"name":91,"class":92},"Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale","NETWORK","100496640","predictive-biomarkers-including-mirna-based-tumor-signatures-in-diffuse-large-b-cell-lymphoma-rr-dlbcl-mimosa-100496640",false,"NCT05746858","Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R\u002FR DLBCL) (MIMOSA)","Deciphering the Biology of Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma (R\u002FR DLBCL) Subtypes: Identification of Predictive Biomarkers Including miRNA-based Tumor Signatures to Optimize Sequential Treatment Decisions. (MIMOSA)","MIMOSA","Inclusion Criteria:\n\n* Diagnosis of DLBCL and RR-DLBCL;\n* Age\\>18 years;\n* Eligibility for first-line and\u002For salvage chemo-immunotherapies as above specified;\n* Measurable and\u002For evaluable disease (at least one bi-dimensionally measurable lesion on imaging scan defined as \\>1.5 cm in its longest dimension);\n* No concomitant active cancers or others life-threatening conditions that can compromise chemotherapy treatment;\n* Available FFPE and fresh tumor tissue (excisional biopsy, Tru-cut microhistology);\n* Informed consent to treatment and use of biologic materials for studies related to the present proposal.\n\nExclusion Criteria:\n\n* Diagnosis of follicular lymphoma grade 3b, lymphoblastic lymphoma, Burkitt lymphoma or primary mediastinal lymphoma;\n* Age ≤ 18 years;\n* Ineligible for first-line and\u002For salvage chemo-immunotherapies;\n* No measurable and\u002For evaluable disease;\n* Patients with concomitant active solid tumors or others clinical conditions that can compromise chemotherapy treatment or negatively influence the prognosis;\n* Known history of HIV seropositive status. HIV testing will be performed at screening","ALL","18 Years",{"count":104,"type":105},300,"ESTIMATED","OBSERVATIONAL","The goal of this study is to identify biomarkers that will predict outcome to standard and targeted therapies in patients with relapsed\u002Frefractory diffuse large B-cell lymphoma (DLBCL). The specific aims of the present project are:\n\n1. To explore associations between expression of target antigens on surface of neoplastic cells of DLBCL patients and response to target therapies\n2. To identify specific miRNA signatures as predictors of response to upfront and salvage immune-chemotherapies in DLBCL patients.\n3. To refine the diagnosis and molecular profiling of DLBCL, and to provide biological information of prognostic relevance in the setting of innovative treatments of patients with DLBCL.",[109,110],"Diffuse Large B Cell Lymphoma","Relapsed Non-Hodgkin Lymphoma",[112,113,114],"miRNA","flow cytometry","next generation sequencing","NOT_YET_RECRUITING","2023-02-17",{"date":118,"type":119},"2023-02-28","ACTUAL",{"date":121,"type":105},"2023-04-01",{"date":123,"type":105},"2027-03-31",{"name":5,"class":6},3]